Bibliographic information
Recommendation
For patients with severe or critical COVID-19. The WHO recommends not to use convalescent plasma for treatment of COVID-19, except in the context of a clinical trial
Recommended against
Strong
Certainty of evidence
Low
Notes and Remarks
Practical Info The GDG made a recommendation against using convalescent plasma in those with severe or critical COVID-19 outside the context of a clinical trial and a strong recommendation against using convalescent plasma for treatment of patients with nonsevere COVID-19. Given this, we will not go into detail regarding the many practical issues related to convalescent plasma including but not limited to: identification and recruitment of potential donors, collection of plasma, storage and distribution of plasma, and infusion of convalescent plasma into recipients.
Also Featured In
This recommendation also appears in the following guidelines:
Therapeutics and COVID-19. Living guideline. 7 December 2021
Therapeutics and COVID-19: living guideline, 3 March 2022.
Therapeutics and COVID-19: living guideline, 22 April 2022.
Therapeutics and COVID-19: living guideline, 14 July 2022.
Therapeutics and COVID-19: living guideline, 16 September 2022.
Therapeutics and COVID-19: living guideline, 13 January 2023.
Therapeutics and COVID-19: living guideline, 10 November 2023.
Therapeutics and COVID-19: living guideline, August 2025